A systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients
These data support the global use of PD-(L)1 inhibitors for Asian and non-Asian patients with 1L or 2L/2L+ locally advanced or metastatic NSCLC. However, it was not possible to assess outcomes in all subgroups due to lack of data (e.g., wider PD-L1 subgroups, genetic profiles), warranting further studies by ethnicity.
Authors
- Nadeem Ghali
- Diego Cortinovis (ORCID: https://orcid.org/0000-0001-7611-7369)
- Pei Jye Voon
- Mesha Austin Taylor
- Sheng Xu
- Nicolas Girard
- Kirsha Naicker
- Lin Zhan
- Solange Peters
- Daniel Tan
- Gilberto Lopes
Institutions
- University of Miami (US)
- Sarawak General Hospital (MY)
- Azienda Ospedaliera San Gerardo (IT)
- National Cancer Centre Singapore (SG)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Sylvester Comprehensive Cancer Center (US)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/tlcr-2025-746
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00